CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: April 23, 2019
Result type: Reports
Project Number: SR0572-000
Product Line: Reimbursement Review

Generic Name: tofacitinib

Brand Name: Xeljanz

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Ulcerative colitis

Indications: Ulcerative colitis

Manufacturer Requested Reimbursement Criteria1: Indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response or intolerance to either conventional UC therapy or a TNFa inhibitor.

Submission Type: Initial

Project Status: Complete

Biosimilar: No

Companion Diagnostics: No

Date Recommendation Issued: February 27, 2019

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule B

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedMay 22, 2018
Patient group input closedJuly 11, 2018

- Patient input submission received from the Gastrointestinal Society

Patient input summary sent for review to patient input groupsJuly 17, 2018
Patient group comments on input summary closedJuly 24, 2018

- Patient input summary feedback received

Submission receivedJune 27, 2018
Submission accepted for reviewJuly 12, 2018
Review initiatedJuly 13, 2018
Draft CADTH review report(s) sent to applicantOctober 10, 2018
Comments from applicant on draft CADTH review report(s) receivedOctober 19, 2018
Redaction requests from applicant on draft CADTH review report(s) receivedOctober 26, 2018
CADTH review team's comments on draft CADTH review report(s) sent to applicantNovember 09, 2018
Canadian Drug Expert Committee (CDEC) meetingNovember 21, 2018
CDEC recommendation & redacted CADTH review report(s) sent to applicant and drug plansDecember 04, 2018
Embargo period ended and validation of redacted CADTH review report(s) receivedDecember 18, 2018

- Reconsideration requested

Applicant's request for reconsideration placed on CDEC agendaFebruary 20, 2019
CDEC Final Recommendation issued to applicant and drug plansFebruary 27, 2019
CDEC Final Recommendation postedMarch 01, 2019
Final CADTH review report(s) and patient input postedMarch 21, 2019